Callisto Pharmaceuticals, Incorporation - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Callisto Pharmaceuticals, Incorporation Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Callisto Pharmaceuticals, Incorporation. The Group's principal activity is developing drugs to treat relapsed acute leukemia, multiple myeloma, and advanced carcinoid cancer patients. Its drug candidate, L-Annamycin, a drug from the anthracycline family completed an initial Phase I/IIa clinical trial. Its second drug candidate, Atiprimod, is an orally administered drug with antiproliferative and antiangiogenic activity completed a Phase I/IIa clinical trial. The company is in a development stage and its operations are located in the United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report